CAS: 1218779-75-9; N-[4-(1-Cyanocyclopentyl)Phenyl]-2-[(4-Pyridinylmethyl)Amino]Nico Tinamide

该化合物是一种小型分子性强血激素活性抑制剂,有选择地针对血管内皮生长因子受体-2(VEGFR-2),主要用于治疗先进的胃癌和其他固态肿瘤,抑制血管生长,抑制肿瘤生长和转移;麻黄盐形式增加溶性,提高生物利用率,改善药用动力特性;主要优点包括VEGFR-2具有高度的特性,减少目标外影响,并显示临床环境中对耐腐性恶性肿瘤患者的疗效;口服治疗为方便提供了方便,并显示出综合疗法的潜力;该化合物具有严格的纯度和稳定性,确保了研究和治疗应用方面的可靠性能.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    甲烷磺酸,阿帕替尼 以 水,异丙醇 用作溶剂,以85.4%的收率获得甲磺酸阿帕替尼
    参考文献:The Salts Of N-[4-(1-Cyanocyclopentyl)Phenyl]-2-(4-Pyridylmethyl)Amino-3-Pyridinecarboxamide
    标题:The Salts Of N-[4-(1-Cyanocyclopentyl)Phenyl]-2-(4-Pyridylmethyl)Amino-3-Pyridinecarboxamide
    摘要:本发明涉及n-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶羧酰胺的盐,特别是其盐酸盐和甲磺酸盐,以及该盐在制备抗肿瘤药物中的应用.

    海关参考信息

    专利信息


    专利号:WO-2023098592-A1
    优先权日:2021-11-30
    标题:Preparation method for carbon-loaded iron-based catalyst and use thereof in synthesis of intermediates of anti-cancer inhibitors

    专利号:US-12390420-B1
    优先权日:2024-10-22
    标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
    发明人:EGUCHI MASAKATSU
    权利人:BRYET US INC
    摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.

    专利号:CN-114315595-B
    优先权日:2021-11-30
    标题 :Preparation method of a carbon-supported iron-based catalyst and its application in the synthesis of anti-cancer inhibitor intermediates

    专利号:US-10272065-B2
    优先权日:2013-01-14
    标题 :Gem-difluorinated C-glycoside compounds as anti-cancer agents
    发明人:SLILATY STEVE N
    权利人:ADVANOMICS CORP; BENOIT & COTE
    摘要:The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.

    专利号:US-2022233727-A1
    优先权日:2019-06-13
    标题:Surface enhanced raman scattering nanoparticles and their use in detecting and imaging oxidative stress
    发明人:THAKOR AVNESH S; RAZAVI MEHDI
    权利人:UNIV LELAND STANFORD JUNIOR
    摘要:Surface enhanced Raman scattering (SERS) nanoparticles and methods of using them for detecting reactive oxygen species are disclosed. In particular, methods of using SERS nanoparticles to detect and quantify reactive oxygen species Synthesis and monitor oxidative stress and disease-relevant changes in levels of reactive oxygen species are provided.

    专利号:CN-114315595-A
    优先权日:2021-11-30
    标题:Preparation method of carbon-supported iron-based catalyst and synthesis application of anti-cancer inhibitor intermediate thereof
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    苏州富士莱医药股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.fuslai.com
    企业联系电话:0512-52838773;52838772👤
    📞苏州富士莱医药股份有限公司 ⚠️参考联系方式
    联系人:陈健
    电话:0512-52838773;52838772

    传真:0512-52831795
    邮箱:sales@fuslai.com
    通信地址: 江苏常熟新材料产业园海旺路16号
    邮编: 215522
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏常熟新材料产业园海旺路16号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Nan T, Cai R, Lian S, Wu X, Wei X, Ye X, Cai Y, Su Y, Wei J. Efficacy and safety of apatinib for the treatment of extensive-stage small cell lung cancer in Chinese patients: a single-arm systematic review and meta-analysis. Chin Clin Oncol. 2025 Dec;14(6):67. doi: 10.21037/cco-25-34.
    16:1653429. doi: 10.3389/fimmu.2025.1653429.
    3: Li Y, Liang Y, Ye P, Chen G, Zhang Y, Chen M, Xiong W, Yang X, Zhang X. Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis. Eur Arch Otorhinolaryngol. 2025 Nov;282(11):5509-5518. doi: 10.1007/s00405-025-09482-x. Epub 2025 May 31. 25(1):564. doi: 10.1186/s12885-025-13932-4.

    合成参考文献


    摘要:Liang S, Tong XZ, Fu LW. [Inhibitory effect of apatinib on HL-60 cell proliferation and its mechanism]. Nan Fang Yi Ke Da Xue Xue Bao. 2011 May;31(5):871–4.
    参考文献:10.1080/07357907.2016.1276185
    摘要:Roviello G, Polom K, Roviello F, Marrelli D, Multari AG, Paganini G, Pacifico C, Generali D. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. Cancer Invest. 2017 Mar 16;35(3):187–94. doi: 10.1080/07357907.2016.1276185.
    参考文献:10.18632/oncotarget.15036
    摘要:Lin Y, Wang C, Gao W, Cui R, Liang J. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget. 2017 Jun 27;8(26):42252–61.
    参考文献:10.1097/md.0000000000016065
    摘要:Jiang Q, Zhang NL, Ma DY, Tan BX, Hu X, Fang XD. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. Medicine (Baltimore). 2019 Jun;98(26):e16065.
    参考文献:10.1002/jcb.29242
    摘要:Gu J, Shu D, Su F, Xie Y, Liang X. Analysis of metabolome changes in the HepG2 cells of apatinib treatment by using the NMR-based metabolomics. J Cell Biochem. 2019 Nov;120(11):19137–46. doi: 10.1002/jcb.29242.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知